A comparative study of the developability of full-length antibodies, fragments, and bispecific formats reveals higher stability risks for engineered constructs

Engineered antibody formats, such as antibody fragments and bispecifics, have the potential to offer improved therapeutic efficacy compared to traditional full-length monoclonal antibodies (mAbs). However, the translation of these non-natural molecules into successful therapeutics can be hampered by...

Full description

Saved in:
Bibliographic Details
Main Authors: Itzel Condado-Morales, Fabian Dingfelder, Isabel Waibel, Oliver M. Turnbull, Bhargav Patel, Zheng Cao, Jais Rose Bjelke, Susanne Nedergaard Grell, Anja Bennet, Alissa M. Hummer, Matthew I. J. Raybould, Charlotte M. Deane, Thomas Egebjerg, Nikolai Lorenzen, Paolo Arosio
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:mAbs
Subjects:
Online Access:https://www.tandfonline.com/doi/10.1080/19420862.2024.2403156
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items